The American pharmaceutical firm had previously forecast $19bn worth of sales from signed contracts for the Covid-19 vaccine this year, with additional purchases forecast at another $500m.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.